ContraFect presents CF-370 data at annual EECMID meeting

ContraFect Corporation announces presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant, XDR, strain of Pseudomonas aeruginosa. These data were recently presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases, ECCMID, Annual Meeting held from April 15-18, 2023 in Copenhagen, Denmark. "The data presented on CF-370 at ECCMID should not be understated. As a physician-scientist who has treated hundreds of immunocompromised patients with either hospital-acquired or ventilator-associated pneumonia, the efficacy of CF-370 against an XDR strain of Pseudomonas in neutropenic animals provides hope for patients struggling to fight against life-threatening, resistant pathogens with a compromised immune system," said Roger Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. "Combined with the data from the presentations of CF-370’s novel mechanism of action against the Gram-negative ESKAPE pathogens, we believe the potential for CF-370 to significantly improve clinical outcomes in HAP/VAP patients continues to dramatically increase."